Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Predictive Value of Reactogenicity for Anti-SARS-CoV-2 Antibody Response in mRNA-1273 Recipients: a Multicenter Prospective Cohort Study

NCT05258708 is registered in ClinicalTrials.gov with Korea University Guro Hospital as lead sponsor.

NCT NCT05258708
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05258708 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Predictive Value of Reactogenicity for Anti-SARS-CoV-2 Antibody Response in mRNA-1273 Recipients: a Multicenter Prospective Cohort Study
Lead sponsor
Korea University Guro Hospital
Phase
Observational
Overall status
Unknown status
Start date
June 24, 2021
Completion date
May 30, 2022
Enrollment
179 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19, vaccine adverse reaction, vaccine immune response